8NOVEMBER 2023IN MY OPINIONBy Rajan Sankaran, Commercial General Manager, CytivaTHE EXCITING POTENTIAL OF DIGITALIZATION IN BIOPHARMA MANUFACTURINGWe are lucky to live in an age where many things can be forecasted. We can predict when our food delivery order will arrive, when a plane will land in real-time and when our target-date funds will mature. For biotech and biopharma companies advancing the next generation of medicines, forecasting is more challenging. They cannot know the success of their therapeutic manufacturing batch for days or weeks after it finishes.Biopharma and biotech manufacturers face many challenges in the biopharma 4.0 era, with speed to market, access to talent, risk mitigation, and cost control being at the top of the list. In addition, biomanufacturing inefficiencies still exist today. Historically, the industry's slower adoption rates of enterprise-wide automation can be attributed to two factors - high implementation costs and slow speed-to-market - resulting in high risks and cost associated with quality problems. Rajan Sankaran
< Page 7 | Page 9 >